News aggregator

The anesthesia isoflurane (brand name Forane) should not be administered to HD patients.

On January 23, 2008, Patient Power will webcast an interview with Jane Paulsen on understanding Huntington's Disease.

Psychologists report on why we do not exercise when we know we should and how we can get motivated.

Brightly colored fruits and vegetables rich in polyphenols help counter the negative effects of high fat food.

Sertaline (Zoloft) improves symptoms, reduces brain atrophy, and prolongs survival in the R6/2 mice.

The Predict-HD study has identified early, subtle, measurable changes that take place 10-20 years before diagnosis.

High throughput screening has identified a compound which inhibits protein aggregation. Part One in a series of three articles. Part 1 of 3.

C2-8 moves another step on the research pipeline with success in a fruitfly model of HD. Part 2 of 3.

Preclinical testing of C2-8 continues to show promise with the R6/2 mice experiencing delayed progression of motor symptoms, smaller aggregates, and reduced cell death. Part 3 of 3.

A loss of BDNF in adult mice leads to overeating and obesity.

In this article, Dr. Goodman wonders how this public debate [discussions about testing for HD] affects those who must make very private and painful decisions.

This is the first in the new series of research updates authored by Marsha L. Miller, Ph.D, that will be appearing weekly on the HDSA website.

This is part 2 of a series of articles reviewing the Huntington’s Disease Community’s Strategic Plan for the Cure. These articles appear on the HDSA Web Site.

This is part 3 of a series of articles reviewing the Huntington’s Disease Community’s Strategic Plan for the Cure. These articles appear on the HDSA Web Site.

The Huntington Study Group’s Inaugural Huntington Disease Clinical Research Symposium was held in Boston on December 1, 2007, and attracted researchers, doctors, family members, and advocates.

Following promising results in mouse models, researchers at Buck Institute and NTI will work on developing FGF-2 as a drug for HD patients.

Research published last week ushers in a new and highly exciting stem cell era. Two groups of scientists from independent laboratories have reprogramed human skin cells to turn into cells that have the same characteristics as embryonic stem cells. Dr Goodman reviews these studies and how they may have impact for Huntington's treatment.

One more Phase III clinical trial is needed to support a New Drug Application.

New research into aging suggests that walnuts as well as the HDL favorite blueberries are good bets for a proactive diet.